Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus

被引:0
作者
Hejun Li
Shunping Lin
Shangchih Yang
Ling Chen
Xiangxiong Zheng
机构
[1] Fujian Medical University,Department of Rheumatology, Union Hospital
[2] Chang Gung Memorial Hospital,Department of Internal Medicine
来源
Clinical Rheumatology | 2015年 / 34卷
关键词
Antinuclear antibody; Complement; Diagnostic value; Systemic lupus erythematosus;
D O I
暂无
中图分类号
学科分类号
摘要
In 2009, hypocomplementemia involving C3, C4, and total hemolytic complement (CH50) was proposed as an immunologic criterion to enhance the sensitivity of systemic lupus erythematosus (SLE) classification criteria. This study evaluated the diagnostic value of low serum complement C3 and C4 levels in Chinese patients with SLE. In total, 2452 patients were enrolled in this study (158 with SLE and 2294 with other diseases). Receiver operating characteristic analysis showed that the optimal C3 and C4 cut-off levels for a diagnosis of SLE were 0.785 g/L (sensitivity, 77.9 %; specificity, 81.5 %) and 0.145 g/L (sensitivity, 80.1 %; specificity, 83.2 %), respectively. The prevalence of a low C3 or C4 level alone was similar between patients with SLE and those with other diseases, while the prevalence of simultaneously low C3 and C4 levels was higher in patients with SLE (73.42 %). Antinuclear antibody had a high sensitivity (96.64 %) and low negative likelihood ratio (0.04). Hypocomplementemia with positive antinuclear antibody had a high positive likelihood ratio. Inclusion of hypocomplementemia as a classification criterion for SLE resulted in a 16.18 % increase in the number of patients assigned to the SLE group (from 136 to 158 patients). Hypocomplementemia was highly prevalent in patients with hematological disease (41.94 %). These results suggest that hypocomplementemia has important diagnostic value for SLE by improving the sensitivity of the diagnosis of SLE. C3 and C4 should be tested simultaneously because a low C3 or C4 level alone is not a suitable immunological criterion.
引用
收藏
页码:471 / 477
页数:6
相关论文
共 70 条
[1]  
Liu CC(2009)The search for lupus biomarkers Best Pract Res Clin Rheumatol 23 507-523
[2]  
Ahearn JM(2009)SLICC revision of the ACR classification criteria for SLE [abstract] Arthritis Rheum 60 895-53
[3]  
Petri M(2014)Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus Clin Exp Rheumatol 32 48-1277
[4]  
Li J(1982)The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 1271-2686
[5]  
An L(1997)Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] Arthritis Rheum 40 1725-2451
[6]  
Zhang Z(2012)Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus Arthritis Rheum 64 2677-1626
[7]  
Tan EM(2012)Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4 Rheumatol Int 32 2445-366
[8]  
Cohen AS(2013)Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity Clin Rheumatol 32 1619-1016
[9]  
Fries JF(1986)Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus Ann Rheum Dis 45 359-584
[10]  
Masi AT(2011)The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus J Rheumatol 38 1012-53